Biocon is currently trading at Rs. 336.40, up by 3.30 points or 0.99% from its previous closing of Rs. 333.10 on the BSE.
The scrip opened at Rs. 333.00 and has touched a high and low of Rs. 337.20 and Rs. 327.20 respectively. So far 17197 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 352.00 on 14-Aug-2013 and a 52 week low of Rs. 243.00 on 22-Aug-2012.
Last one week high and low of the scrip stood at Rs. 352.00 and Rs. 324.00 respectively. The current market cap of the company is Rs. 6630.00 crore.
The promoters holding in the company stood at 60.96% while Institutions and Non-Institutions held 17.99% and 21.04% respectively.
Biocon, Asia’s premier biotechnology company, has launched its ‘first in class’ novel biologic ALZUMAb (Itolizumab), the world’s first anti-CD6 monoclonal antibody to be introduced for treating patients with chronic plaque psoriasis, in India.
ALZUMAb with a unique Mechanism of Action (MOA) offers superior safety and similar efficacy profile compared to other existing therapies, and has a long remission period with very low opportunistic infection rate. Psoriasis is a socially debilitating disease affecting 2-3% of world population. The global Psoriasis market size is estimated to cross $8 billion by 2016.
Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.
